|
Volavka, J; Cooper, T B; Czobor, P et al. (2000) High-dose treatment with haloperidol: the effect of dose reduction. J Clin Psychopharmacol 20:252-6
|
|
Czobor, P; Volavka, J (1996) Dimensions of the Brief Psychiatric Rating Scale: an examination of stability during haloperidol treatment. Compr Psychiatry 37:205-15
|
|
Czobor, P; Volavka, J (1996) Positive and negative symptoms: is their change related? Schizophr Bull 22:577-90
|
|
Volavka, J; Cooper, T B; Czobor, P et al. (1996) Effect of varying haloperidol plasma levels on negative symptoms in schizophrenia and schizoaffective disorder. Psychopharmacol Bull 32:75-9
|
|
Volavka, J; Cooper, T B; Laska, E M et al. (1996) Placebo washout in trials of antipsychotic drugs. Schizophr Bull 22:567-76
|
|
Volavka, J; Cooper, T B; Czobor, P et al. (1995) Plasma haloperidol levels and clinical effects in schizophrenia and schizoaffective disorder. Arch Gen Psychiatry 52:837-45
|
|
Convit, A; Volavka, J; Czobor, P et al. (1994) Effect of subtle neurological dysfunction on response to haloperidol treatment in schizophrenia. Am J Psychiatry 151:49-56
|
|
Krakowski, M I; Kunz, M; Czobor, P et al. (1993) Long-term high-dose neuroleptic treatment: who gets it and why? Hosp Community Psychiatry 44:640-4
|
|
Czobor, P; Volavka, J (1993) Quantitative electroencephalogram examination of effects of risperidone in schizophrenic patients. J Clin Psychopharmacol 13:332-42
|
|
Volavka, J; Cooper, T; Czobor, P et al. (1992) Haloperidol blood levels and clinical effects. Arch Gen Psychiatry 49:354-61
|
Showing the most recent 10 out of 16 publications
